Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis
A 34-year-old white woman, with a 22-year history of refractory and destructive RA, had been treated with a long list of disease-modifying antirheumatic drugs (gold salts, thiopronine, d -penicillamine, sulfasalazine, azathioprine, ciclosporin, methotrexate (MTX) and etanercept). Rheumatoid factor w...
Gespeichert in:
| Veröffentlicht in: | Annals of the rheumatic diseases 2008-06, Vol.67 (6), p.893-894 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 894 |
|---|---|
| container_issue | 6 |
| container_start_page | 893 |
| container_title | Annals of the rheumatic diseases |
| container_volume | 67 |
| creator | Marotte, H Paintaud, G Watier, H Miossec, P |
| description | A 34-year-old white woman, with a 22-year history of refractory and destructive RA, had been treated with a long list of disease-modifying antirheumatic drugs (gold salts, thiopronine, d -penicillamine, sulfasalazine, azathioprine, ciclosporin, methotrexate (MTX) and etanercept). Rheumatoid factor was positive and antinuclear and anti-DNA antibodies were negative. Because of persistent active disease (28 joint count Disease Activity Score 5.86) despite treatment with MTX (25 mg/week), etanercept (50 mg/week) and prednisone (10 mg/day), rituximab (two 1 g infusions at a 2-week interval) was started, combined with MTX and steroids in December 2005. |
| doi_str_mv | 10.1136/ard.2007.081166 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_00616939v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4008464001</sourcerecordid><originalsourceid>FETCH-LOGICAL-b429t-b32b21005362b5c8d10c83dee3c857b6ee0f127a45bbd10de8af69ada75eef703</originalsourceid><addsrcrecordid>eNqF0M-L1DAUB_Agijuunr1JQDwodPalaX70uAyuK44Ksu6Cl5C0r0zGmXZM0nX9703pMB69JCTvk8fLl5CXDJaMcXlhQ7ssAdQSNGNSPiILVkldlCDhMVkAAC-qWqoz8izGbT5mpp-SM6YrVUmhF-T2m0_jg99bVwTc2YQtndZi6CMm2uOYwnDA3lvqe2rpwSaPfaK_fdrQiPcYkIYNjnubBt9SG9Im-OTjc_Kks7uIL477Ofl-9f5mdV2sv374uLpcF64q61Q4XrqSAQguSyca3TJoNG8ReaOFchIROlYqWwnncq1FbTtZ29Yqgdgp4Ofk7dx3Y3fmEPI_wh8zWG-uL9dmugOQTNa8vmfZvp7tIQy_RozJbIcx9Hk8w5RSWggtJnUxqyYMMQbsTm0ZmClzkzM3U-Zmzjy_eHXsO7o9tv_8MeQM3hyBjY3ddcH2jY8nVwKvtIYqu2J2PiZ8ONVt-Gmk4kqYL7crc_dpLX98vrozN9m_m73bb_875V_fbaZE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777855851</pqid></control><display><type>article</type><title>Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><creator>Marotte, H ; Paintaud, G ; Watier, H ; Miossec, P</creator><creatorcontrib>Marotte, H ; Paintaud, G ; Watier, H ; Miossec, P</creatorcontrib><description>A 34-year-old white woman, with a 22-year history of refractory and destructive RA, had been treated with a long list of disease-modifying antirheumatic drugs (gold salts, thiopronine, d -penicillamine, sulfasalazine, azathioprine, ciclosporin, methotrexate (MTX) and etanercept). Rheumatoid factor was positive and antinuclear and anti-DNA antibodies were negative. Because of persistent active disease (28 joint count Disease Activity Score 5.86) despite treatment with MTX (25 mg/week), etanercept (50 mg/week) and prednisone (10 mg/day), rituximab (two 1 g infusions at a 2-week interval) was started, combined with MTX and steroids in December 2005.</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/ard.2007.081166</identifier><identifier>PMID: 18474658</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><subject>Adult ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal, Murine-Derived ; Antirheumatic Agents - adverse effects ; Arthritis, Rheumatoid - drug therapy ; Arthritis, Rheumatoid - immunology ; Biological and medical sciences ; Bone marrow ; Disease ; Diseases of the osteoarticular system ; Female ; Granulocytes ; Hematologic and hematopoietic diseases ; Humans ; Immunomodulators ; Inflammatory joint diseases ; Life Sciences ; Lymphoma ; Medical sciences ; Neutropenia ; Neutropenia - chemically induced ; Other diseases. Hematologic involvement in other diseases ; Pharmacology. Drug treatments ; Rheumatoid arthritis ; Rituximab ; Time</subject><ispartof>Annals of the rheumatic diseases, 2008-06, Vol.67 (6), p.893-894</ispartof><rights>2008 BMJ Publishing Group and European League Against Rheumatism</rights><rights>2008 INIST-CNRS</rights><rights>Copyright: 2008 2008 BMJ Publishing Group and European League Against Rheumatism</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b429t-b32b21005362b5c8d10c83dee3c857b6ee0f127a45bbd10de8af69ada75eef703</citedby><orcidid>0000-0003-1177-9497 ; 0000-0003-0158-1356 ; 0000-0002-2139-4171</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/67/6/893.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/67/6/893.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,230,314,780,784,885,3196,23571,27924,27925,77600,77631</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20348804$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18474658$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-00616939$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Marotte, H</creatorcontrib><creatorcontrib>Paintaud, G</creatorcontrib><creatorcontrib>Watier, H</creatorcontrib><creatorcontrib>Miossec, P</creatorcontrib><title>Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>A 34-year-old white woman, with a 22-year history of refractory and destructive RA, had been treated with a long list of disease-modifying antirheumatic drugs (gold salts, thiopronine, d -penicillamine, sulfasalazine, azathioprine, ciclosporin, methotrexate (MTX) and etanercept). Rheumatoid factor was positive and antinuclear and anti-DNA antibodies were negative. Because of persistent active disease (28 joint count Disease Activity Score 5.86) despite treatment with MTX (25 mg/week), etanercept (50 mg/week) and prednisone (10 mg/day), rituximab (two 1 g infusions at a 2-week interval) was started, combined with MTX and steroids in December 2005.</description><subject>Adult</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal, Murine-Derived</subject><subject>Antirheumatic Agents - adverse effects</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Arthritis, Rheumatoid - immunology</subject><subject>Biological and medical sciences</subject><subject>Bone marrow</subject><subject>Disease</subject><subject>Diseases of the osteoarticular system</subject><subject>Female</subject><subject>Granulocytes</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Inflammatory joint diseases</subject><subject>Life Sciences</subject><subject>Lymphoma</subject><subject>Medical sciences</subject><subject>Neutropenia</subject><subject>Neutropenia - chemically induced</subject><subject>Other diseases. Hematologic involvement in other diseases</subject><subject>Pharmacology. Drug treatments</subject><subject>Rheumatoid arthritis</subject><subject>Rituximab</subject><subject>Time</subject><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqF0M-L1DAUB_Agijuunr1JQDwodPalaX70uAyuK44Ksu6Cl5C0r0zGmXZM0nX9703pMB69JCTvk8fLl5CXDJaMcXlhQ7ssAdQSNGNSPiILVkldlCDhMVkAAC-qWqoz8izGbT5mpp-SM6YrVUmhF-T2m0_jg99bVwTc2YQtndZi6CMm2uOYwnDA3lvqe2rpwSaPfaK_fdrQiPcYkIYNjnubBt9SG9Im-OTjc_Kks7uIL477Ofl-9f5mdV2sv374uLpcF64q61Q4XrqSAQguSyca3TJoNG8ReaOFchIROlYqWwnncq1FbTtZ29Yqgdgp4Ofk7dx3Y3fmEPI_wh8zWG-uL9dmugOQTNa8vmfZvp7tIQy_RozJbIcx9Hk8w5RSWggtJnUxqyYMMQbsTm0ZmClzkzM3U-Zmzjy_eHXsO7o9tv_8MeQM3hyBjY3ddcH2jY8nVwKvtIYqu2J2PiZ8ONVt-Gmk4kqYL7crc_dpLX98vrozN9m_m73bb_875V_fbaZE</recordid><startdate>20080601</startdate><enddate>20080601</enddate><creator>Marotte, H</creator><creator>Paintaud, G</creator><creator>Watier, H</creator><creator>Miossec, P</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>BMJ</general><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-1177-9497</orcidid><orcidid>https://orcid.org/0000-0003-0158-1356</orcidid><orcidid>https://orcid.org/0000-0002-2139-4171</orcidid></search><sort><creationdate>20080601</creationdate><title>Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis</title><author>Marotte, H ; Paintaud, G ; Watier, H ; Miossec, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b429t-b32b21005362b5c8d10c83dee3c857b6ee0f127a45bbd10de8af69ada75eef703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal, Murine-Derived</topic><topic>Antirheumatic Agents - adverse effects</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Arthritis, Rheumatoid - immunology</topic><topic>Biological and medical sciences</topic><topic>Bone marrow</topic><topic>Disease</topic><topic>Diseases of the osteoarticular system</topic><topic>Female</topic><topic>Granulocytes</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Inflammatory joint diseases</topic><topic>Life Sciences</topic><topic>Lymphoma</topic><topic>Medical sciences</topic><topic>Neutropenia</topic><topic>Neutropenia - chemically induced</topic><topic>Other diseases. Hematologic involvement in other diseases</topic><topic>Pharmacology. Drug treatments</topic><topic>Rheumatoid arthritis</topic><topic>Rituximab</topic><topic>Time</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marotte, H</creatorcontrib><creatorcontrib>Paintaud, G</creatorcontrib><creatorcontrib>Watier, H</creatorcontrib><creatorcontrib>Miossec, P</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marotte, H</au><au>Paintaud, G</au><au>Watier, H</au><au>Miossec, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2008-06-01</date><risdate>2008</risdate><volume>67</volume><issue>6</issue><spage>893</spage><epage>894</epage><pages>893-894</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>A 34-year-old white woman, with a 22-year history of refractory and destructive RA, had been treated with a long list of disease-modifying antirheumatic drugs (gold salts, thiopronine, d -penicillamine, sulfasalazine, azathioprine, ciclosporin, methotrexate (MTX) and etanercept). Rheumatoid factor was positive and antinuclear and anti-DNA antibodies were negative. Because of persistent active disease (28 joint count Disease Activity Score 5.86) despite treatment with MTX (25 mg/week), etanercept (50 mg/week) and prednisone (10 mg/day), rituximab (two 1 g infusions at a 2-week interval) was started, combined with MTX and steroids in December 2005.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><pmid>18474658</pmid><doi>10.1136/ard.2007.081166</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0003-1177-9497</orcidid><orcidid>https://orcid.org/0000-0003-0158-1356</orcidid><orcidid>https://orcid.org/0000-0002-2139-4171</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-4967 |
| ispartof | Annals of the rheumatic diseases, 2008-06, Vol.67 (6), p.893-894 |
| issn | 0003-4967 1468-2060 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_00616939v1 |
| source | MEDLINE; BMJ Journals - NESLi2 |
| subjects | Adult Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Murine-Derived Antirheumatic Agents - adverse effects Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - immunology Biological and medical sciences Bone marrow Disease Diseases of the osteoarticular system Female Granulocytes Hematologic and hematopoietic diseases Humans Immunomodulators Inflammatory joint diseases Life Sciences Lymphoma Medical sciences Neutropenia Neutropenia - chemically induced Other diseases. Hematologic involvement in other diseases Pharmacology. Drug treatments Rheumatoid arthritis Rituximab Time |
| title | Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T23%3A31%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rituximab-related%20late-onset%20neutropenia%20in%20a%20patient%20with%20severe%20rheumatoid%20arthritis&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Marotte,%20H&rft.date=2008-06-01&rft.volume=67&rft.issue=6&rft.spage=893&rft.epage=894&rft.pages=893-894&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/ard.2007.081166&rft_dat=%3Cproquest_hal_p%3E4008464001%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777855851&rft_id=info:pmid/18474658&rfr_iscdi=true |